The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1359
March 7, 2011
View Complete Issue         Table of Contents 2019 
Alcaftadine (Lastacaft) for Allergic Conjunctivitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Alcaftadine (Lastacaft) for Allergic Conjunctivitis
March 7, 2011 (Issue: 1359)
Alcaftadine (Lastacaft – Allergan), an ophthalmic H1-antihistamine, has been approved by the FDA for prevention of itching associated with allergic conjunctivitis in patients > 2 years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Alcaftadine (Lastacaft) for Allergic Conjunctivitis
Article code: 1359c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.